{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:43:02Z","timestamp":1786164182850,"version":"build-2736575974"},"reference-count":26,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematol. Rep.","Hematology Reports"],"abstract":"<jats:p>Background\/Objectives: Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for relapsed or refractory multiple myeloma (RRMM). Although prior analyses have summarized teclistamab outcomes, some have included combination regimens or broader comparative studies. Given the expanding real-world experience with teclistamab, we conducted a systematic review and meta-analysis focused on teclistamab monotherapy in RRMM. Methods: We performed a systematic review and meta-analysis of clinical trials and retrospective real-world studies evaluating teclistamab monotherapy in RRMM. The primary endpoint was overall response rate (ORR). Secondary endpoints included complete response (CR), overall mortality rate (OMR), mortality due to multiple myeloma progression, teclistamab-attributed mortality, adverse event-related mortality, grade \u22653 cytokine release syndrome (CRS), grade \u22653 immune effector cell-associated neurotoxicity syndrome (ICANS), and other grade \u22653 adverse events. Pooled proportions were estimated using random-effects models. Results: Twelve studies including 761 patients were analyzed, comprising two clinical trials and ten real-world retrospective cohorts. The pooled ORR was 60.9%, and the pooled CR rate was 25.2%. The pooled OMR was 26.9%, with mortality due to myeloma progression of 23.9%, adverse event-related mortality of 8.1%, and teclistamab-attributed mortality of 3.3%. Severe (grade \u22653) CRS and ICANS were uncommon, with grade \u22653 events occurring in 1.7% and 3.1%, respectively. Grade \u22653 infections occurred in 28.3%. Common grade \u22653 hematologic adverse events included lymphopenia, neutropenia, anemia, and thrombocytopenia. Conclusions: Teclistamab monotherapy demonstrates meaningful clinical activity and a manageable immune toxicity profile in heavily pretreated RRMM. However, severe infections and hematologic toxicities remain important clinical considerations, supporting the need for close monitoring, infection prevention, and supportive care during therapy.<\/jats:p>","DOI":"10.3390\/hematolrep18040054","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:26:52Z","timestamp":1785778012000},"page":"54","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2824-4202","authenticated-orcid":false,"given":"Jerry","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Francisco, Fresno Campus, 155 N. Fresno Street, Fresno, CA 93701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0331-892X","authenticated-orcid":false,"given":"Pranati","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Akhtari","sequence":"additional","affiliation":[{"name":"Division of Transplant, Cellular Therapy, and Hematological Malignancies, Department of Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"Knop","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Padala, S.A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., and Ajebo, G.H. (2021). Epidemiology, staging, and management of multiple myeloma. Med. Sci., 9.","DOI":"10.3390\/medsci9010003"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell\u2013redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1007\/s00277-024-06078-z","article-title":"Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: A systematic review and meta-analysis","volume":"103","author":"Qureshi","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Li, W., Zhao, D., Jiao, Y., Dong, W., Wang, Z., and Yan, X. (2025). Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: A systematic review and meta-analysis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1565407"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"ref_13","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2026, June 24). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale."},{"key":"ref_14","unstructured":"Sch\u00fcnemann, H.J., Higgins, J.P.T., Vist, G.E., Glasziou, P., Akl, E.A., Skoetz, N., and Guyatt, G.H. (2026, June 24). Chapter 14: Completing \u2018Summary of Findings\u2019 Tables and Grading the Certainty of the Evidence. Available online: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-14."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1182\/blood-2022-158801","article-title":"Teclistamab for relapsed\/refractory multiple myeloma: Real-world experience in an early access program","volume":"140","author":"Uttervall","year":"2022","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1016\/S2152-2650(23)01466-0","article-title":"MM-527 Real world evaluation of teclistamab for the treatment of relapsed or refractory Multiple Myeloma (RRMM)","volume":"23","author":"Maringanti","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2023-190793","article-title":"Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM)","volume":"142","author":"Asoori","year":"2023","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1182\/blood-2023-180421","article-title":"Real-world safety and efficacy of teclistamab for patients with heavily pretreated relapsed\/refractory multiple myeloma","volume":"142","author":"Dima","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood-2023-184928","article-title":"Teclistamab induces favorable responses in patients with relapsed and refractory multiple myeloma after prior BCMA-directed therapy","volume":"142","author":"Castaneda","year":"2023","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1200\/JCO.2023.41.16_suppl.8049","article-title":"Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies","volume":"41","author":"Firestone","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e19504","DOI":"10.1200\/JCO.2024.42.16_suppl.e19504","article-title":"Real-world outcomes of teclistamab for the treatment of relapsed\/refractory multiple myeloma at UC San Diego Health: A single-institution experience","volume":"42","author":"Ghamsari","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: Multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e20044","DOI":"10.1200\/JCO.2023.41.16_suppl.e20044","article-title":"Efficacy of teclistamab in patients with heavily pretreated, relapsed\/refractory multiple myeloma (RRMM), including those refractory to penta RRMM and BCMA-directed therapy (BDT)","volume":"41","author":"Venkatesh","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S967","DOI":"10.1016\/S2152-2650(25)02689-8","article-title":"MM-1139: Safety and efficacy of teclistamab in the management of relapsed\/refractory multiple myeloma: A meta-analysis","volume":"25","author":"Qi","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/54\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:11:03Z","timestamp":1786162263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/18\/4\/54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["hematolrep18040054"],"URL":"https:\/\/doi.org\/10.3390\/hematolrep18040054","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}